Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04796896 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate Safety and Effectiveness of mRNA-1273 COVID-19 Vaccine in Healthy Children Between 6 Months of Age and Less Than 12 Years of Age
A Phase 2 study, sponsored by ModernaTX.
- Completed
- Registry status
- Phase 2
- Development phase
- 11,942
- Enrollment target
NCT04796896 is a Phase 2 study that has completed, run by ModernaTX. The registered enrollment target is 11,942 participants.
The verdict
NCT04796896, a Phase 2 study, has completed, sponsored by ModernaTX.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 11,942 participants
- Enrollment target
Study Summary
The primary goal for this study is to evaluate up to 3 dose levels of mRNA-1273 vaccine given to healthy children as intramuscular (IM) injection in 2 doses (in Parts 1 and 2) and 3 doses (in Part 3), and a third dose or an optional booster dose (BD) (in Parts 1 and 2).
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL mRNA-1273
- BIOLOGICAL mRNA-1273.214
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11,942 participants |
| Start Date | 2021-03-15 |
| Est. Completion | 2024-03-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04796896
The ClinicalTrials.gov registry entry for NCT04796896 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 11,942 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ModernaTX, which has 90 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT04796896 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04796896 about?
NCT04796896 is a clinical study titled "A Study to Evaluate Safety and Effectiveness of mRNA-1273 COVID-19 Vaccine in Healthy Children Between 6 Months of Age and Less Than 12 Years of Age". The primary goal for this study is to evaluate up to 3 dose levels of mRNA-1273 vaccine given to healthy children as intramuscular (IM) injection in 2 doses (in Parts 1 and 2) and 3 doses (in Part 3), and a third dose or an optional booster dose (BD) (in Parts 1 and 2).
What is the current status of trial NCT04796896?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 11,942 participants. The study started on 2021-03-15. Estimated completion is 2024-03-15.
What interventions are being tested in trial NCT04796896?
The interventions under investigation include: Placebo (BIOLOGICAL), mRNA-1273 (BIOLOGICAL), mRNA-1273.214 (BIOLOGICAL).
Who is sponsoring clinical trial NCT04796896?
This trial is sponsored by ModernaTX, which has 90 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.